ONLINE WORKSHOP
October 07, 2023 Online Live Workshop
Discern between the various anxiety and panic disorder presentations in patients, and corresponding neural pathophysiology
Assess the socio-economic and public health impact of anxiety and panic disorder in the Australian population
Demonstrate the skills, and the knowledge required for a comprehensive assessment for patients suffering from anxiety and panic disorders
Create a patient-centred treatment plan considering non- pharmacological and pharmacological approaches
Distinguish various indications and contraindications to prescribe medicinal cannabis for patients suffering from anxiety or panic disorders
Medihuanna is a CPD approved education provider, and this activity has been approved by the RACGP (Activity ID: 469731). Upon completing this activity, you will be eligible to claim CPD hours. The activity will include the following CPD allocation which will be uploaded to the RACGP dashboard.
Educational Activity: 2 hours
Reviewing Performance: 5 hours
Measuring Outcomes: 5 hours
Medical Educator
This Comprehensive Management of Anxiety and Panic Disorders has been developed and conducted by experienced medical practitioners managing patients suffering from Anxiety and Panic Disorders. Based on their experience you will receive a comprehensive overview of this common indication, statistics, causes, comorbidities, pathophysiology and current treatments.
Our educators will prepare you to manage more patients by providing an in-depth review of current treatments, identifying the advantages and limitations to ensure each treatment plan is patient centred and designed to give your patients the best therapeutic outcome.
Upon completion of this masterclass, through interactive group activities and practical case studies you will learn how to manage patients better, and gain the knowledge to reduce polypharmacy and provide an integrative approach by incorporating plant-based medicines.
Approximately 44% of Australians aged 16-85, or 8.6 million individuals, are believed to have experienced a mental disorder at some point in their life, with 21%, or 4.2 million individuals, experiencing a mental disorder within the last 12 months.
Anxiety disorders, such as Social Phobia, affect the highest number of Australians, with an estimated 17%, or 3.3 million individuals, affected, followed by Affective disorders, such as Depressive Episode, which affect 8%, and Substance Use disorders, such as Alcohol Dependence, which affect 3%. Among children and adolescents aged 4-17 years, an estimated 14% are believed to have experienced a mental illness within the last 12 months.
Roughly 5%, or 800,000 people, have a severe mental illness, with 500,000 people experiencing episodic mental illness and 300,000 experiencing persistent mental illness. Mental and substance use disorders are the second largest contributor, at 24%, to the non-fatal burden of disease in Australia.
The results from a recent study showed that anxiety was one of the most common conditions for which medical cannabis was prescribed, accounting for approximately 26% of all approvals in Australia. The study also found that patients with anxiety were more likely to use cannabis strains with higher levels of CBD, which is a non-psychoactive compound that has been shown to have anxiolytic properties. Overall, these findings suggest that medicinal cannabis may be an effective treatment option for anxiety, and that a significant percentage of patients have already been approved for its use.
It is crucial for healthcare practitioners to adopt an integrative approach to patient management and to have a comprehensive understanding of current conventional and plant-based treatments, their advantages, and limitations. A holistic and patient-centred approach that provides individualised treatment plans is necessary to achieve the best therapeutic outcomes for patients.
This online activity is conducted live through our platform that comes with 2 hours of lectures and 2 hours of interactive exercises, case studies and clinical applications. The remaining 8 hour module will be completed self-paced after the live component has concluded. For more information please download the program outline.
Claim CPD Hours
7th of October 2023
08:30 - 14:00 AEDT
Registration closes 6th of October 2023
CPD allocation with reporting to your CPD home available
Statement of Attendance available to become an Authorised Prescriber
© Medihuanna Pty Ltd, 2023. All rights reserved.